NYSE · GILD
Healthcare · Drug Manufacturers - General
$166.89
Down-$0.68 (-0.41%)
Updated Nov 8, 2026, 8:20 AM
SID Score
7.8/10
Composite research score
Smart Money
44/100
Neutral
Price performance · GILD
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 6, 2026
GILD closed at $166.89 after 20 trading sessions, up 10.94% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | $164.11 | $169.06 | $164.00 | $166.89 | 5.82M |
| Nov 5, 2026 | $174.54 | $176.58 | $167.09 | $167.57 | 11.36M |
| Nov 4, 2026 | $171.89 | $175.41 | $168.84 | $174.48 | 9.64M |
| Nov 3, 2026 | $170.27 | $172.00 | $167.43 | $167.47 | 6.61M |
| Nov 2, 2026 | $169.85 | $172.61 | $166.38 | $170.33 | 8.88M |
| Oct 30, 2026 | $170.25 | $175.65 | $169.00 | $170.68 | 11.43M |
| Oct 29, 2026 | $162.89 | $165.70 | $160.86 | $165.61 | 8.43M |
| Oct 28, 2026 | $157.28 | $160.83 | $156.04 | $159.20 | 5M |
| Oct 27, 2026 | $156.05 | $159.28 | $155.76 | $159.08 | 4.93M |
| Oct 26, 2026 | $157.62 | $159.69 | $157.5201 | $158.69 | 6.05M |
| Oct 23, 2026 | $156.47 | $157.65 | $155.76 | $156.04 | 6.07M |
| Oct 22, 2026 | $154.24 | $157.42 | $153.00 | $157.19 | 6.21M |
| Oct 21, 2026 | $154.73 | $155.42 | $151.71 | $153.57 | 6.22M |
| Oct 20, 2026 | $155.37 | $157.48 | $154.02 | $156.51 | 5.79M |
| Oct 19, 2026 | $155.385 | $157.24 | $152.92 | $153.07 | 6.84M |
| Oct 16, 2026 | $157.32 | $157.575 | $155.62 | $156.19 | 7.77M |
| Oct 15, 2026 | $156.39 | $160.51 | $156.02 | $157.37 | 8.29M |
| Oct 14, 2026 | $148.19 | $153.76 | $147.48 | $153.54 | 5.76M |
| Oct 13, 2026 | $151.16 | $151.16 | $147.26 | $147.92 | 6.23M |
| Oct 12, 2026 | $151.835 | $152.26 | $149.80 | $150.43 | 5.79M |
The latest Smart Investors Daily articles mentioning GILD.
Company
Market Activity
Research & News
GILD research
Company profile and research snapshot.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | Scotiabank | Sector Outperform | — |
| Oct 30, 2026 | RBC Capital | Sector Perform | — |
| Oct 30, 2026 | Truist Securities | Buy | — |
| Oct 30, 2026 | Morgan Stanley | Overweight | — |
| Oct 30, 2026 | Needham | Buy | — |
No generated briefing is available yet.
Yahoo · Nov 7, 2026
A red ink EPS figure usually spells trouble for retirees counting on a payout. Gilead's loss traces back to one strange quarter, and a single cash metric reveals whether the dividend checks are really at risk.
Benzinga · Nov 6, 2026
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.47% on an annualized basis producing an average annual return of 12.13%. Currently, Gilead Sciences has a market capitalization of
Yahoo · Nov 6, 2026
FOSTER CITY, Calif., November 06, 2026--New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
Benzinga · Nov 6, 2026
Gilead Sciences, Inc. (NASDAQ:GILD) today announced results from the PURPOSE 5 trial showing significantly higher persistence—defined as consistent and continuous on-time use—among people starting twice-yearly
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GILD.
